97302 ⎘
Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen Internalization into the cell
AXL-SPECIFIC ANTIBODY-DRUG CONJUGATES FOR CANCER TREATMENT
#302Peptides
#303ANTI-CD73 ANTIBODY AND USE THEREOF
#304ANTIBODY CONSTRUCTS FOR DLL3 AND CD3
#305MUSCLE-TARGETING COMPLEXES AND USES THEREOF
#306Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
#307ANTI-TIM3 ANTIBODIES AND METHODS OF USE
#308Antigen Binding Proteins
#309IMMUNO-BASED BOTULINUM TOXIN SEROTYPE A ACTIVITY ASSAYS
#310Muscle targeting complexes and uses thereof for treating dystrophinopathies
#311ANTIBODIES TO CD70
#312CELL PENETRATING PROTEIN-ANTIBODY CONJUGATES AND METHODS OF USE
#313Humanized Anti-GPC-1 Antibody
#314Anti-sclerostin antibodies and methods of use
#315IMMUNO-BASED BOTULINUM TOXIN SEROTYPE A ACTIVITY ASSAYS
#316COMPOSITIONS AND METHODS FOR DELIVERY OF NUCLEIC ACIDS TO CELLS
#317TUMOR SELECTIVE MACROPINOCYTOSIS-DEPENDENT RAPIDLY INTERNALIZING ANTIBODIES
#318METHODS AND COMPOSITIONS FOR INHIBITING CD32B EXPRESSING CELLS IN IGG4-RELATED DISEASES
#319BIFUNCTIONAL BRIDGING COMPOSITIONS FOR VIRAL TRANSDUCTION
#320Polynucleotides encoding antibodies which bind the EC3 domain of cadherin-6 (CDH6) and possess internalization ability
#321ANTIBODIES WITH MODIFIED AFFINITY TO FCRN THAT PROMOTE ANTIGEN CLEARANCE
#322ROR1 ANTIBODIES
#323CYSTEINE LINKED NANOBODY DIMERS
#324NOVEL ANTI-CD3EPSILON ANTIBODIES
#325ROR1-SPECIFIC ANTIGEN BINDING MOLECULES
#326Anti-LY6H antibodies and antibody drug conjugates
#327NOVEL ANTI-CD3EPSILON ANTIBODIES
#328ANTI-ROR-2 ANTIBODIES AND METHODS OF USE
#329BISPECIFIC ANTIBODY TARGETING TRANSFERRIN RECEPTOR 1 AND SOLUBLE ANTIGEN
#330Antibody molecules and conjugates
#331NUCLEOLIN-MEDIATED CANCER DIAGNOSTICS AND THERAPY
#332CD40 BINDING PROTEIN
#333TREM2 STABILIZING ANTIBODIES
#334Membrane Ubiquitin ligases to target protein degradation
#335MONOCLONAL ANTIBODIES FOR INTRACELLULAR DELIVERY OF PAYLOADS
#336Phage-displayed accessible recombinant targeted antibodies and methods of making same
#337ANTIGEN BINDING PROTEINS
#338Anti-TREM1 antibodies and methods of use thereof
#339Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
#340Bispecific antigen binding constructs targeting HER2
#341METHOD OF STIMULATING ASYMMETRIC DIVISION OF SATELLITE STEM CELLS
#342ANTI-NTB-A ANTIBODIES AND RELATED COMPOSITIONS AND METHODS
#343Compositions and methods for delivery of nucleic acids to cells
#344FUSION PROTEINS FOR SELECTIVELY DEPLETING ANTIGEN-SPECIFIC ANTIBODIES
#345ANTI-PD-L1 ANTIBODIES
#346Compositions and methods for delivery of nucleic acids to cells
#347ANTI-MULLERIAN HORMONE RECEPTOR 2 ANTIBODIES AND METHODS OF USE
#348METHODS FOR DNA-DEPENDENT TARGETING OF A CELL PERMEANT ANTIBODY
#349ANTI-PD-L1 ANTIBODIES
#350Anti-CD300F antibody and uses thereof
#351HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED DEATH LIGAND 1 (PD-L1)
#352ANTI-IL-1-BETA ANTIBODIES
#353PHOTOSENSITIZING ANTIBODY-FLUOROPHORE CONJUGATES
#354Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
#355COMPOSITIONS AND METHODS FOR REGULATING CAR T CELLS
#356Compositions and methods for delivery of nucleic acids to cells
#357COMPOSITIONS AND METHODS FOR THE CYTOPLASMIC DELIVERY OF ANTIBODIES AND OTHER PROTEINS
#358ANTIGEN LOADING
#359GRP78-binding antibodies and uses thereof in detecting or neutralizing GRP78
#360ANTI-MUC16 ANTIBODIES AND USES THEREOF
#361RADIOHALOGEN PROSTHETIC MOIETIES AND RADIOLABELED BIOMOLECULES
#362Muscle targeting complexes and uses thereof for treating dystrophinopathies
#363RECOMBINANT MONOVALENT ANTIBODIES AND METHODS FOR PRODUCTION THEREOF
#364BINDING PROTEINS TO CUB DOMAIN-CONTAINING PROTEIN (CDCP1)
#365BISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO PD1 AND LAG3
#366Binding molecules specific for FcγRIIA and uses thereof
#367ANTIBODIES AND METHODS OF USE
#368CLAUDIN18 ANTIBODIES AND METHODS OF TREATING CANCER
#369COMPOUNDS AND METHODS TARGETING EPIREGULIN
#370ANTI-TIM3 ANTIBODIES AND METHODS OF USE
#371Humanized complement 5A receptor 1 antibodies and methods of use thereof
#372GRP78-binding antibodies and uses thereof in detecting or neutralizing GRP78
#373ANTIBODY BINDING SPECIFICALLY TO B7-H3 AND USE THEREOF
#374ANTI-CEACAM5 ANTIBODIES AND USES THEREOF
#375ANTI-STEM CELL FACTOR ANTIBODIES AND METHODS OF USE THEREOF
#376ANTI-CXCR2 ANTIBODIES AND USES THEREOF
#377ANTI-IgE CONSTRUCT
#378ANTIGEN-BINDING PROTEIN CONSTRUCTS AND USES THEREOF
#379ANTIGEN-BINDING MOLECULE FOR PROMOTING CLEARANCE FROM PLASMA OF ANTIGEN COMPRISING SUGAR CHAIN RECEPTOR-BINDING DOMAIN
#380ANTI-STEM CELL FACTOR ANTIBODIES AND METHODS OF USE THEREOF IN RENAL DISEASE
#381LIGANDS TARGED TO EPIDERMAL GROWTH FACTOR RECEPTORS AND COMPOSITIONS FOR USE IN TREATING TUMORS
#382A SINGLE-DOMAIN ANTIBODY FOR TARGETING PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA)
#383GRP78-binding antibodies and uses thereof and selection of phage-displayed accessible recombinant targeted antibodies
#384Therapeutic binding molecules
#385ANTI-VSIG4 ANTIBODY OR ANTIGEN BINDING FRAGMENT AND USES THEREOF
#386ANTIGEN-BINDING PROTEIN CONSTRUCTS AND USES THEREOF
#387Anti-TMEFF1 antibodies and antibody drug conjugates
#388Immunomodulatory antibodies and methods of use thereof
#389Muscle targeting complexes and uses thereof for treating dystrophinopathies
#390Photosensitizing antibody-fluorophore conjugates
#391Weekly dosing regimens for anti-CD30 vc-PAB-MMAE antibody drug-conjugates
#392Anti-myostatin antibodies and methods of use
#393ANTIBODIES RECOGNIZING TAU
#394METHODS OF MAKING MULTISPECIFIC ANTIGEN-BINDING MOLECULES
#395BINDING MEMBERS
#396ANTI-CD45 ANTIBODIES AND CONJUGATES THEREOF
#397METHODS OF USING ANTIBODIES RECOGNIZING TAU
#398ANTIBODIES BINDING TO GPRC5D
#399BISPECIFIC ANTIBODIES SPECIFIC FOR PD1 AND TIM3
#400Anti-B7-H4 antibodies and immunoconjugates
#401BISPECIFIC BINDING PROTEINS AND USES THEREOF
#402METHODS AND COMPOSITIONS RELATING TO ANTI-NUCLEOLIN RECOMBINANT IMMUNOAGENTS
#403BI-SPECIFIC BINDING AGENTS TARGETING SYNDECAN-1 AND FIBROBLAST GROWTH FACTOR RECEPTOR
#404PROVASOPRESSIN ANTAGONISTS AND USES THEREOF
#405HUMANIZED ANTIBODIES TO MUCIN-16 AND METHODS OF USE THEREOF
#406METHODS FOR DNA-DEPENDING TARGETING OF A CELL PERMEANT ANTIBODY
#407ANTI-ROR1 / ANTI-CD3 BISPECIFIC BINDING MOLECULES
#408Anti-ILT3 antibodies and antibody drug conjugates
#409High-affinity anti-MERTK antibodies and uses thereof
#410Antibody specific for CD22 and methods of use thereof
#411Methods of treating neurodegenerative diseases
#412CHIMERIC PROTEINS FOR TARGETING dsRNA
#413COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMOR
#414ANTIBODIES AGAINST PROGRAMMED CELL DEATH PROTEIN 1 (PD1) AND USES THEREOF
#415Methods of treating HLA-E-expressing cancers by administering antibodies which bind human natural killer cell inhibitory receptor group 2A (NKG2A)
#416VARIABLE LYMPHOCYTE RECEPTORS THAT TARGET THE BLOOD BRAIN BARRIER AND METHODS OF USE
#417Nucleic acid molecules encoding antibodies which bind natural killer cell inhibitory receptor group 2A protein (NKG2A)
#418Compositions and methods for internalizing enzymes
#419Novel bispecific binding molecule and drug conjugate thereof
#420ANTI-AXL ANTIBODIES
#421CLAUDIN-6 BISPECIFIC ANTIBODIES
#422BISPECIFIC ANTIBODIES AND USES THEREOF
#423ANTIBODY VARIANTS WITH PH-DEPENDENT ANTIGEN BINDING FOR SELECTIVE TARGETING OF SOLID TUMORS
#424METHODS AND COMPOSITIONS FOR ANTI-CD73 ANTIBODIES AND VARIANTS
#425ANTI-CD73 MONOCLONAL ANTIBODY AND APPLICATION THEREOF
#426Anti-B7-H4 antibodies and immunoconjugates
#427ANTI-CD33 ANTIBODIES AND METHODS OF USE THEREOF
#428ANTI-CD79B ANTIBODY, ANTIGEN-BINDING FRAGMENT THEREOF, AND PHARMACEUTICAL USE THEREOF
#429IMMUNO-BASED BOTULINUM TOXIN SEROTYPE A ACTIVITY ASSAYS
#430Muscle targeting complexes and uses thereof for treating dystrophinopathies
#431INTERNALIZING BINDING MOLECULES TARGETING RECEPTORS INVOLVED IN CELL PROLIFERATION OR IN CELL DIFFERENTIATION
#432J591 MINIBODIES AND CYS-DIABODIES FOR TARGETING HUMAN PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) AND METHODS FOR THEIR USE
#433Humanized anti-CCR7 receptor antibodies
#434CONJUGATES FOR TREATING INFLAMMATORY DISEASE AND IDENTIFICATION OF PATIENTS LIKELY TO BENEFIT FROM SUCH TREATMENT
#435Anti-CD94 antibodies and methods of use thereof
#436Site-specific glycoengineering of targeting moieties
#437PLECTIN-1 BINDING ANTIBODIES AND USES THEREOF
#438CDCP1-TARGETED THERAPIES
#439Therapeutic molecules
#440BI-SPECIFIC ANTIBODIES FOR ENHANCED TUMOR SELECTIVITY AND INHIBITION AND USES THEREOF
#441ANTIBODIES COMPRISING MODIFIED HEAVY CONSTANT REGIONS
#442Anti Human Interleukin-1 Receptor Accessory Protein (IL1 RAP) Antibodies and Uses Thereof
#443ANTI-CD40 ANTIBODIES FOR USE IN TREATMENT OF HIDRADENITIS
#444Antigen binding proteins
#445METHODS OF NEUTRALIZING IL-8 BIOLOGICAL ACTIVITY
#446MODULATING PTPN2 TO INCREASE IMMUNE RESPONSES AND PERTURBING GENE EXPRESSION IN HEMATOPOIETIC STEM CELL LINEAGES
#447Isoform-selective TGFB1 inhibitors and use thereof
#448ANTI-TCR ANTIBODY MOLECULES AND USES THEREOF
#449Glycan-Interacting Compounds and Methods of Use
#450NOVEL POLYPEPTIDES
#451ANTIBODIES AGAINST THE MUC1-C/EXTRACELLULAR DOMAIN (MUC1-C/ECD)
#452BAFF-R antibodies and uses thereof
#453Bispecific antibody targeting IL-1R1 and NLPR3
#454MODIFIED ANTIBODY FCS AND METHODS OF USE
#455Bispecific antibody targeting IL-1R1 and NLPR3
#456Bifunctional molecules for lysosomal targeting and related compositions and methods
#457ANTIBODY VARIABLE DOMAINS TARGETING DLL3, AND USE THEREOF
#458Anti-B7-H3 antibody, preparation method therefor, conjugate and application thereof
#459Anti-kit antibodies and uses thereof
#460BAFF-R targeted chimeric antigen receptor-modified T-cells and uses thereof
#461Multispecific antigen-binding molecules and uses thereof
#462Bispecific antigen-binding constructs targeting HER2
#463Antigen-binding constructs targeting HER2
#464HUMAN ANTIBODY DRUG CONJUGATES AGAINST TISSUE FACTOR
#465METHODS AND COMPOSITIONS FOR INHIBITING CD32B EXPRESSING CELLS
#466Site-specific conjugation of linker drugs to antibodies and resulting ADCs
#467ANTI-DLL3 ANTIBODY
#468COMBINATION THERAPY USING AN ANTI-FUCOSYL-GM1 ANTIBODY AND AN ANTI-CD137 ANTIBODY
#469Fusion proteins comprising extracellular domain of human CD22
#470LY75 AS CANCER THERAPEUTIC AND DIAGNOSTIC TARGET
#471COMPOSITIONS AND METHODS FOR ENHANCING DONOR OLIGONUCLEOTIDE-BASED GENE EDITING
#472Immuno-based botulinum toxin serotype A activity assays
#473VACCINES AGAINST ANTIGENS INVOLVED IN THERAPY RESISTANCE AND METHODS OF USING SAME
#474BISPECIFIC ANTIBODIES AGAINST HER2
#475MONOCLONAL ANTIBODIES SPECIFIC FOR FIBROBLAST GROWTH FACTOR RECEPTOR 4 (FGFR4) AND METHODS OF THEIR USE
#476MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING FIBRODYSPLASIA OSSIFICANS PROGRESSIVA
#477Anti-CD117 antibodies and conjugates
#478BI-SPECIFIC BINDING MOLECULES
#479Weekly dosing regimens for anti-CD30 vc-PAB-MMAE antibody drug-conjugates
#480Antibodies to MUC16 and methods of use thereof
#481Antibody constructs for DLL3 and CD3
#482MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING FRIEDREICH'S ATAXIA
#483MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING DYSTROPHINOPATHIES
#484Fusion proteins comprising an anti-CD40 antibody and cancer antigens
#485COMPLEX CAPABLE OF INHIBITING GENETIC FUNCTION IN EXOSOME, AND CANCER PROLIFERATION AND/OR METASTASIS SUPPRESSOR
#486BISPECIFIC ANTIGEN BINDING MOLECULES WITH TRIVALENT BINDING TO CD40
#487Anti-Siglec antibody, pharmaceutical composition comprising the same, and uses thereof
#488ANTI-CD74 ANTIBODIES, COMPOSITIONS COMPRISING ANTI-CD74 ANTIBODIES AND METHODS OF USING ANTI-CD74 ANTIBODIES
#489Anti-PSMA antibodies and use thereof
#490Epitope specific antibodies that bind cell surface GRP78 and their use for cancer detection
#491BINDER/ACTIVE AGENT CONJUGATES DIRECTED AGAINST CXCR5, HAVING ENZYMATICALLY CLEAVABLE LINKERS AND IMPROVED ACTIVITY PROFILE
#492Anti-human CD19 antibodies
#493NOVEL ANTI-BMPR1B ANTIBODIES AND METHODS OF USE
#494Human CD163 antibodies and uses thereof
#495Anti-TIM-3 antibodies and methods of use thereof
#496ANTI-TROP2 ANTIBODY-DRUG CONJUGATE
#497HIGH AFFINITY MONOCLONAL ANTIBODIES (MABS) AGAINST CELL SURFACE EXPRESSED HUMAN CARBONIC ANHYDRASE IX (HCA-IX), AND USES THEREOF
#498Glucose transporter 4 antibodies, methods of making the same, and uses thereof
#499Monoclonal antibody anti-FGFR4
#500Antibody binding TIM-3 and use thereof
#501BCMA monoclonal antibody-drug conjugate
#502Dual specificity antibodies to PD-L1 and PD-L2 and methods of use therefor
#503CLDN 18.2-specific monoclonal antibodies and methods of use thereof
#504Therapeutic antibodies against ROR-1 protein and methods for use of same
#505Compositions and methods to enhance the immune system
#506Methods of using bispecific antigen-binding constructs targeting HER2
#507Human monoclonal antibodies to ganglioside GD2
#508Method of eliminating hematopoietic stem cells/hematopoietic progenitors (HSC/HP) in a patient using bi-specific antibodies
#509B7-H3 directed antibody drug conjugates
#510Immuno-based botulinum toxin serotype A activity assays
#511Antibody variants and uses thereof
#512ASGR INHIBITORS
#513COMPOSITIONS AND METHODS FOR THE DEPLETION OF CD117+ CELLS
#514Method of treating or ameliorating metabolic disorders using GLP-1 receptor agonists conjugated to antagonists for gastric inhibitory peptide receptor (GIPR)
#515ANTIBODIES AND USES THEREOF
#516Anti-EGFRvIII antibodies and uses thereof
#517Antibodies and molecules that immunospecifically bind to BTN1A1 and the therapeutic uses thereof
#518ANTI-CD71 ACTIVATABLE ANTIBODY DRUG CONJUGATES AND METHODS OF USE THEREOF
#519Optimized Fc variants
#520Anti-CD33 antibodies and methods of use thereof
#521Anti-CD33 and anti-CD7 combination treatment
#522Weekly dosing regimens for anti-CD30 vc-PAB-MMAE antibody drug-conjugates
#523Anti-MET antibodies and methods of use thereof
#524Antibody binding specifically to ECL-2 of claudin 3, fragment thereof, and use thereof
#525Multispecific antigen-binding molecules binding to a target and an internalizing effector protein that is CD63 and uses thereof
#526Pharmaceutical combinations
#527PROSTATE-SPECIFIC MEMBRANE ANTIGEN BINDING PROTEINS AND RELATED COMPOSITIONS AND METHODS
#528Antibody drug conjugates (ADC) that bind to 158P1D7 proteins
#529Anti-Siglec-9 antibodies and methods of use thereof
#530Combination therapy of T cell activating bispecific antigen binding molecules and PD-1 axis binding antagonists
#531Treatment with anti-KIR3DL2 agents
#532Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
#533Antigen-binding molecule capable of binding two or more antigen molecules repeatedly
#534THERAPEUTIC AND DIAGNOSTIC TARGET FOR CANCER COMPRISING DLL3 BINDING REAGENTS
#535Anti-CD63 antibodies, conjugates, and uses thereof
#536Anti-stem cell factor antibodies and methods of blocking the interaction between SCF and c-Kit
#537Radiolabeled MET binding proteins for immuno-PET imaging and methods of use thereof
#538Antibody-drug conjugates and uses thereof
#539ANTIBODIES BINDING TO GPRC5D
#540Anti-Siglec-7 antibodies having reduced effector function
#541METHODS AND COMPOSITIONS FOR TREATMENT OF POLYGLUCOSAN DISORDERS
#542ANTIBODIES AGAINST BST1 FOR PREVENTING OR TREATING MYELODYSPLASTIC SYNDROME
#543Targeted CD73 antibody and antibody-drug conjugate, and preparation method therefor and uses thereof
#544Binding molecules specific for ASCT2 and uses thereof
#545IGF-1R ANTIBODY AND ITS USE FOR THE DIAGNOSIS OF CANCER
#546Glycan-Interacting Compounds and Methods of Use
#547Anti-CD39 antibodies
#548METHODS AND COMPOSITIONS FOR INHIBITING CD32B EXPRESSING CELLS
#549METHODS AND COMPOSITIONS FOR INHIBITING CD32B EXPRESSING CELLS
#550CKIT antibody drug conjugates
#551Anti-annexin A2 monoclonal antibodies
#552AXL-SPECIFIC ANTIBODY-DRUG CONJUGATES FOR CANCER TREATMENT
#553Therapeutic molecules
#554Anti-CD43 antibody and use thereof for cancer treatment
#555IMMUNO-BASED BOTULINUM TOXIN SEROTYPE A ACTIVITY ASSAYS
#556Anti-CDH6 antibody and anti-CDH6 antibody-drug conjugate
#557Anti-KIT antibodies and uses thereof
#558Antibody-Mediated Transduction Of Heat Shock Proteins Into Living Cells
#559Signal molecules as cell penetration agents
#560Anti-STEAP2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind STEAP2 and CD3, and uses thereof
#561Anti-STAT3 bispecific antibody having cell-penetrating ability, and pharmaceutical composition containing same
#562MOLECULES THAT BIND TO CD137 AND PSMA
#563Single domain antibodies that bind to CD137
#564Humanized anti-CCR7 receptor antibodies
#565Anti-GPR20 antibody and anti-GPR20 antibody-drug conjugate
#566ROR1 antibodies
#567METHODS OF MODULATING INFLAMMASOME ACTIVITY TO TREAT INFLAMMATORY CONDITIONS
#568Methods of producing an IL-1 RAP antibodies
#569ANTI-ILT7 ANTIBODY
#570ANTI-ROR1 ANTIBODY AND CONJUGATES THEREOF
#571Inert format
#572Anti-CD73 antibodies and uses thereof
#573Antibody constructs for DLL3 and CD3
#574Anti-ERBB-2 antibodies and uses thereof
#575Optimized antibodies that target CD19
#576Compositions and methods for treating age-related diseases
#577TfR selective binding compounds and related methods
#578Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
#579Therapeutic antibodies against ROR-1 protein and methods for use of same
#580ANTI-GPC-1 ANTIBODY
#581Anti-LY6H antibodies and antibody drug conjugates
#582Anti-CD115 antibodies
#583HER3 antigen-binding molecules
#584Weekly dosing regimens for anti-CD30 vc-PAB-MMAE antibody drug-conjugates
#585ANTIBODIES COMPRISING MODIFIED HEAVY CONSTANT REGIONS
#586Anti-CD3epsilon antibodies
#587ERIBULIN-BASED ANTIBODY-DRUG CONJUGATES AND METHODS OF USE
#588Anti-TIM-3 antibodies and methods of use thereof
#589High-affinity anti-MERTK antibodies and uses thereof
#590TREATMENT OF CANCER USING CHIMERIC ANTIGEN RECEPTOR
#591Antibody-drug conjugate
#592Anti-TIM-3 antibodies and methods of use thereof
#593Cysteine engineered antigen-binding molecules
#594AXL-specific antibodies and uses thereof
#595Anti-CD303 Monoclonal Antibodies
#596Antibody variants
#597Anti-ErbB3 antibodies and uses thereof
#598Bispecific antibodies against HER2 and CD3
#599Anti-TM4SF1 antibodies and methods of using same
#600ANTIBODIES COMPRISING MODIFIED HEAVY CONSTANT REGIONS